Terms: = Sarcomas AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
437 results:
1. Correlations between the modification patterns mediated by pyroptosis-related genes, tumor microenvironment, and immunotherapy in soft tissue sarcoma.
Cai Y; Meng J; Qiu Y; Huang X; Du H; Yao J
Medicine (Baltimore); 2024 May; 103(20):e38173. PubMed ID: 38758862
[TBL] [Abstract] [Full Text] [Related]
2. Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC.
Bao Z; Yu X; Zheng K; Zhai K; Cui H; Xu M
Front Immunol; 2024; 15():1372279. PubMed ID: 38756778
[TBL] [Abstract] [Full Text] [Related]
3. Clinical and Biologic Correlates of ADORA2A Transcriptomic Expression in Cancer.
Shreenivas A; Nishizaki D; Lee S; Pabla S; Nesline M; Conroy JM; DePietro P; Kato S; Kurzrock R
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731962
[TBL] [Abstract] [Full Text] [Related]
4. PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6
De Wispelaere W; Annibali D; Tuyaerts S; Messiaen J; Antoranz A; Shankar G; Dubroja N; Herreros-Pomares A; Baiden-Amissah REM; Orban MP; Delfini M; Berardi E; Van Brussel T; Schepers R; Philips G; Boeckx B; Baietti MF; Congedo L; HoWangYin KY; Bayon E; Van Rompuy AS; Leucci E; Tabruyn SP; Bosisio F; Mazzone M; Lambrechts D; Amant F
Clin Transl Med; 2024 May; 14(5):e1655. PubMed ID: 38711203
[TBL] [Abstract] [Full Text] [Related]
5. New advances in the treatment of chondrosarcoma under the pd-1/PD-L1 pathway.
Yin J; Ren P
J Cancer Res Ther; 2024 Apr; 20(2):522-530. PubMed ID: 38687921
[TBL] [Abstract] [Full Text] [Related]
6. [Detection and Significance of Molecular Markers in Immunotherapy and Targeted Therapy of Colorectal Cancer in Tibet].
Luo HH; Liu BY; Huo Z; BIANbazhaxi ; Wang Q; DUObula ; NImazhuoma ; DA Z; Wang H; Guo PP
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Apr; 46(2):184-192. PubMed ID: 38686714
[TBL] [Abstract] [Full Text] [Related]
7. LncRNA NEAT1 promotes MPP+ induced injury of PC12 cells and accelerates the progression of Parkinson's disease in mice through FUS mediated inhibition of PI3K/AKT/mTOR signalling pathway.
Wang Y; Li Z; Li J; Sun C
Exp Gerontol; 2024 Jun; 191():112436. PubMed ID: 38636570
[TBL] [Abstract] [Full Text] [Related]
8. Radiotherapy combined with anti-pd-1 and TKI for primary cardiac angiosarcoma considering the joint assessment of TLSs and PD-L1: a case report.
Deng S; Yang X; He L; Zhang Q; Zhao C; Meng H
J Cardiothorac Surg; 2024 Apr; 19(1):194. PubMed ID: 38594687
[TBL] [Abstract] [Full Text] [Related]
9. Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study.
Liao Z; Teng J; Li T; Liu H; Li T; Zhang C; Xing R; Teng S; Yang Y; Zhao J; Xiao W; Zhang G; Li MJ; Yao W; Yang J
Front Immunol; 2024; 15():1292325. PubMed ID: 38585276
[TBL] [Abstract] [Full Text] [Related]
10. A synergistic approach for modulating the tumor microenvironment to enhance nano-immunotherapy in sarcomas.
Mpekris F; Panagi M; Charalambous A; Voutouri C; Michael C; Papoui A; Stylianopoulos T
Neoplasia; 2024 May; 51():100990. PubMed ID: 38520790
[TBL] [Abstract] [Full Text] [Related]
11. The Development and Characterization of a Next-Generation Oncolytic Virus Armed with an Anti-pd-1 sdAb for Osteosarcoma Treatment
Higgins TA; Patton DJ; Shimko-Lofano IM; Eller TL; Molinari R; Sandey M; Ismail A; Smith BF; Agarwal P
Cells; 2024 Feb; 13(4):. PubMed ID: 38391964
[TBL] [Abstract] [Full Text] [Related]
12. A first-in-human phase I study of the pd-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).
Lakhani N; Cosman R; Banerji U; Rasco D; Tomaszewska-Kiecana M; Garralda E; Kornacki D; Li J; Tian C; Bourayou N; Powderly J
ESMO Open; 2024 Apr; 9(4):102254. PubMed ID: 38387109
[TBL] [Abstract] [Full Text] [Related]
13. Immunohistochemistry assessment of tissue neutrophil-to-lymphocyte ratio predicts outcomes in melanoma patients treated with anti-programmed cell death 1 therapy.
Teixeira RJ; de Souza VG; Sorroche BP; Paes VG; Zambuzi-Roberto FA; Pereira CAD; Vazquez VL; Arantes LMRB
Melanoma Res; 2024 Jun; 34(3):234-240. PubMed ID: 38364053
[TBL] [Abstract] [Full Text] [Related]
14. Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-pd1-resistant cancer patients.
Tan Q; Gao R; Zhang X; Yang J; Xing P; Yang S; Wang D; Wang G; Wang S; Yao J; Zhang Z; Tang L; Yu X; Han X; Shi Y
Cancer Immunol Immunother; 2024 Feb; 73(3):47. PubMed ID: 38349411
[TBL] [Abstract] [Full Text] [Related]
15. Network pharmacology and experimental validation to study the potential mechanism of Tongguanteng injection in regulating apoptosis in osteosarcoma.
Wei L; Meng J; Xiang D; Yang Q; Zhou Y; Xu L; Wang M; Chen J; Han Y
BMC Complement Med Ther; 2024 Jan; 24(1):67. PubMed ID: 38297292
[TBL] [Abstract] [Full Text] [Related]
16. Unraveling T cell exhaustion in the immune microenvironment of osteosarcoma via single-cell RNA transcriptome.
Cheng D; Zhang Z; Liu D; Mi Z; Tao W; Fu J; Fan H
Cancer Immunol Immunother; 2024 Jan; 73(2):35. PubMed ID: 38280005
[TBL] [Abstract] [Full Text] [Related]
17. Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant pd-1 based immunotherapy.
Taylor AM; McKeown J; Dimitriou F; Jacques SK; Zimmer L; Allayous C; Yeoh HL; Haydon A; Ressler JM; Galea C; Woodford R; Kahler K; Hauschild A; Festino L; Hoeller C; Schwarze JK; Neyns B; Wicky A; Michielin O; Placzke J; Rutkowski P; Johnson DB; Lebbe C; Dummer R; Ascierto PA; Lo S; Long GV; Carlino MS; Menzies AM
Eur J Cancer; 2024 Mar; 199():113561. PubMed ID: 38278009
[TBL] [Abstract] [Full Text] [Related]
18. Immune characteristics of dedifferentiated retroperitoneal liposarcomas and the reliability of regional samples in evaluating their tumor immune microenvironments.
Zhou C; Li M; Ren Y; Miao F; Wang Y; Wu T; Gou X; Li W
World J Surg Oncol; 2024 Jan; 22(1):25. PubMed ID: 38254190
[TBL] [Abstract] [Full Text] [Related]
19. Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue sarcomas: Clinical Outcomes and Biological Correlates.
Haddox CL; Nathenson MJ; Mazzola E; Lin JR; Baginska J; Nau A; Weirather JL; Choy E; Marino-Enriquez A; Morgan JA; Cote GM; Merriam P; Wagner AJ; Sorger PK; Santagata S; George S
Clin Cancer Res; 2024 Apr; 30(7):1281-1292. PubMed ID: 38236580
[TBL] [Abstract] [Full Text] [Related]
20. Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-pd-1 treatment.
Baginska J; Nau A; Gomez Diaz I; Giobbie-Hurder A; Weirather J; Vergara J; Abrecht C; Hallisey M; Dennis J; Severgnini M; Huezo J; Marciello I; Rahma O; Manos M; Brohl AS; Bedard PL; Renouf DJ; Sharon E; Streicher H; Ott PA; Buchbinder EI; Hodi FS
Cancer Immunol Immunother; 2024 Jan; 73(1):17. PubMed ID: 38236249
[TBL] [Abstract] [Full Text] [Related]
[Next]